Read Time: 9 mins

Retifanlimab and Other Immune Checkpoint Inhibitors for Squamous Cell Anal Carcinoma

Copy Link
Published Online: Mar 8th 2023 touchREVIEWS in Oncology & Haematology. 2023;9(1):41-5 DOI:
Authors: Justin Mencel, Sheela Rao
Quick Links:
Article Information

Metastatic squamous cell anal carcinoma (SCAC) accounts for almost 500 deaths per year in the UK. The optimal first-line treatment for metastatic SCAC consists of combination chemotherapy, which provides only modest benefit with a short duration of response. Currently, there is no established second-line treatment for chemorefractory disease. Retifanlimab (a programmed cell death protein 1 inhibitor) has shown promise in patients with refractory, metastatic SCAC based on the POD1UM-202 study, and has potential in the first-line setting in combination with chemotherapy. This article will review the current treatment paradigms for SCAC, including the future use of immune checkpoint inhibitors, with a focus on retifanlimab in the treatment of SCAC.


Anal cancer, chemotherapy, human papillomavirus, immune checkpoint inhibitorsimmunotherapysquamous cell carcinoma


Cancers of the anal canal are relatively uncommon, and account for less than 1% of all new cancer diagnoses in the UK.1 However, the incidence of these cancers has increased over the past decade, primarily in females, in which they have more than doubled.1 Squamous cell anal carcinoma (SCAC) is the most common type of anal cancer, with adenocarcinomas, neuroendocrine carcinomas and melanomas being less common. Between 80% and 95% of these cancers are associated with the human papillomavirus (HPV).2–5 Another risk factor includes immunosuppression caused by, for example, HIV infection and organ transplantation.6

Most patients with SCAC present with localized or loco-regional disease, which is potentially curable. Definitive chemoradiotherapy with concurrent mitomycin C and fluorouracil is considered the standard approach in this setting and is associated with high cure rates in up to 60% of patients.7 In those with relapsed and/or metastatic SCAC, platinum-based chemotherapy is the mainstay of treatment, with carboplatin and paclitaxel considered the optimal regimen.8 Although associated with relatively high response rates (objective response rate [ORR] 59%), chemotherapy frequently provides short-lived responses. Prolonged, durable responses to platinum-based chemotherapy are uncommon, with most patients’ disease progressing within 9 months.8 In the second-line, chemorefractory setting, there are limited chemotherapy treatment options with established evidence in the treatment of metastatic SCAC, all with varying benefit and toxicities.

The use of immune checkpoint inhibitors (ICIs) is of particular interest in SCAC given the immunogenicity seen in these HPV-related cancers. The HPV oncoproteins (mostly E6 and E7) induce transformation from normal squamous epithelium to an invasive malignancy through inactivation of cell cycle proteins.9 These oncoproteins can induce immune escape through activation of programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) interaction, which downregulates tumour-infiltrating lymphocytes (TILs) and other immune regulatory cells.10,11 Blocking this pathway with ICIs can promote T-cell activation and enhance the host immune response, triggering tumour cell death. The rationale for the use of ICIs in the treatment of SCAC is based on the greater immunogenicity seen in these tumours relative to other, non-HPV-related cancer types. This article aims to review the current treatment landscape of SCAC, including the future use of ICI, with a focus on retifanlimab. We searched PubMed in August 2022. Search criteria and keywords used include “squamous cell anal carcinoma”, “immune-checkpoint” and “retifanlimab”. Only interventional studies were included in this review.

Retifanlimab as a programmed cell death protein 1 inhibitor

Retifanlimab is a humanized immunoglobulin G4 monoclonal antibody against PD-1 that blocks the interaction between PD-1 and PD-L1. It has activity against several solid tumours in the advanced setting, including gastric cancer.12 However, most of the evidence for its use is in the treatment of metastatic SCAC, with established safety and efficacy in the later-line setting. The POD1UM-202 trial was the first phase II study assessing the use of retifanlimab in the second- or later-line setting of locally recurrent or metastatic SCAC.13 Patients who had progressed on prior platinum-based chemotherapy were considered suitable for this study. The majority of patients enrolled had distant metastases (80.9%), 9.6.0% of patients had HIV infection, and 66% of patients had a PD-L1 tumour proportion score of ≥1%. Single-agent retifanlimab was intravenously administered at a dose of 500 mg every 4 weeks. Retifanlimab was associated with an impressive ORR of 13.8% (the study’s primary endpoint), including one complete response and a disease control rate of 48.9%. The median duration of response was 9.5 months. Responses were seen regardless of HIV infection, presence of liver metastases or age. The median overall survival (mOS) was 10.1 months, providing a signal of efficacy for the use of retifanlimab as a treatment option in those with chemorefractory SCAC. Although POD1UM-202 had no comparator arm, the mOS in those treated with retifanlimab is considered longer compared with single-agent chemotherapy in the second line. This study also aimed to investigate potential biomarkers of response to anti-PD-1 therapies; however, there was no association between tumour mutational burden (<10 mutations/Mb versus 10 mutations/Mb) and PD-L1 status on response, which is considered a predictive biomarker of response to ICI in other tumour types. In addition, there was no deterioration in HIV control in patients treated with retifanlimab, including no increase in the incidence of opportunistic infections. This is of particular importance given the risks of myelosuppression seen with cytotoxic chemotherapy. However, randomized data comparing chemotherapy with ICIs in this population is needed to assess efficacy and safety.

Importantly, retifanlimab was relatively well tolerated with treatment-related adverse events (TRAEs) of any grade seen in 58.0% of participants, with only 11.7% grade 3. The most common TRAEs were itch, fatigue, diarrhoea and nausea. Only 25.0% of patients experienced an immune-related adverse event (irAE), mostly related to endocrinopathy, skin involvement or pneumonitis (with pneumonitis leading to treatment discontinuation in one patient). The treatment discontinuation rate secondary to irAE was only 2.1%, considerably lower compared with other PD-1 inhibitors.

The POD1UM-202 study demonstrated the safety and efficacy of single-agent retifanlimab in patients with relapsed or metastatic SCAC, following progression on platinum-based chemotherapy. The efficacy of retifanlimab seems to be comparable to other PD(L)1 inhibitors that have also been assessed in the treatment of advanced SCAC, as outlined in Table 1.13–17 Retifanlimab is currently being investigated in the first-line, phase III POD1UM-303/InterAACT 2 study ( Identifier: NCT04472429) of chemotherapy with or without retifanlimab in patients with relapsed or metastatic SCAC (as discussed below).18

Other anti-PD(L)-1 agents in squamous cell anal carcinoma

Pembrolizumab is another PD-1 monoclonal antibody that has demonstrated clinical activity and safety in treating a range of advanced solid cancers, including SCAC. The KEYNOTE-028 phase Ib study assessed the use of pembrolizumab as monotherapy in patients with PD-L1-positive (i.e. 1%) advanced SCAC, following progression on at least one prior line of chemotherapy.19 Twenty-five patients were treated with single-agent pembrolizumab (10 mg/kg every 2 weeks). The primary endpoints were safety and ORR. Pembrolizumab was associated with an ORR of 17.0% and a disease control rate of 58.0%. TRAEs were seen in 64% of patients, most commonly diarrhoea and fatigue. There were no treatment-related deaths or discontinuation due to toxicities. Interestingly, one patient with non-squamous histology had evidence of stable disease, demonstrating possible activity even in less common subtypes of anal cancer. However, larger clinical trials are needed to validate this finding.

The KEYNOTE-158 phase II study further assessed the efficacy of pembrolizumab in a larger cohort of patients with locally advanced or metastatic SCAC in the second- or later-line setting.14 Unlike in the KEYNOTE-028 study, this study did not exclude patients who were <1% PD-L1-positive. Of the 112 patients enrolled and treated, 67.0% had PD-L1 positivity (1%), with 93.0% had metastatic disease. However, this study excluded patients with HIV infection, which were included in the POD1UM-202 study. Pembrolizumab was given at a dose of 200 mg every 3 weeks for up to 2 years. The ORR was 11.6%; however,ORR was slightly higher in those with PD-L1-positive tumours compared with PD-L1-negative tumours (15.0% versus 3.0%). The mOS was 11.9 months in all enrolled patients. Although 61.0% of patients had at least one TRAE, only 18.0% were considered grade 34. The KEYNOTE-158 study demonstrated efficacy and safety for the use of pembrolizumab as monotherapy in previously treated SCAC, regardless of PD-L1 expression.


Another PD-1 inhibitor, nivolumab, has also demonstrated safety and efficacy in the treatment of SCAC. The NCI9673 phase II single-arm study assessed the use of nivolumab in patients with treatment-refractory, advanced SCAC.15 In an unselected PD-L1 population, 37 patients were treated with nivolumab at a dose of mg/kg every 2 weeks. The ORR (primary endpoint) was 24.0%, with a complete response rate of 5.0%. One of the two patients who were HIV-positive that were included in this study had a partial radiographic response to nivolumab. Median progression-free survival (mPFS) was 4.1 months and mOS was 11.5 months. This is comparable to the survival data seen with pembrolizumab and retifanlimab in a similar cohort of patients. Unlike in the POD1UM-202 study, PD-L1 expression correlated with response rate, with responders having higher levels of PD-L1 expression compared with non-responders. However, this post hoc analysis only included a small sample size and further validation studies are needed to fully assess the validity of PD-L1 as a predictive biomarker of response to ICI in SCAC. In addition, larger studies assessing the use of nivolumab (and other PD(L)1 inhibitors) in those with active HIV infection are needed to confirm the findings of the NCI9673 and POD1UM-202 studies.


Avelumab is an anti-PD-L1 agent that has efficacy and safety in patients with SCAC. The CARACAS study was a non-comparative, randomized phase II trial assessing the use of avelumab with or without cetuximab (anti-epidermal growth factor receptor [EGFR] monoclonal antibody) in the second- or later-line treatment of advanced SCAC.16 HPV-associated SCAC is characterized by high expression of EGFR, and combining ICI with anti-EGFR antibodies may theoretically enhance responses in SCAC.20 Patients were randomized to either avelumab with cetuximab (n=30) or avelumab alone (n=30). ORR (primary endpoint) was 10.0% with avelumab alone, compared with 16.7% when combined with cetuximab. The mPFS was longer in the combination avelumab with cetuximab arm compared with the avelumab alone arm (3.9 months versus 2.0 months). However, this did not translate to prolonged survival, with a mOS of 13.9 months in the monotherapy arm compared with 7.8 months in the combination arm. This study, however, was not designed to compare the two arms, with the authors concluding that the small sample size in both arms was a contributing factor for the incongruent result. Treatment with cetuximab and avelumab did slightly increase the rate of grade 3–4 TRAEs. This combination is not currently considered standard of care in the second-line setting of advanced SCAC, and further larger studies are needed to provide support for the use of avelumab (with or without EGFR inhibition) to understand the impact on survival.


Atezolizumab is another PD-L1 inhibitor that has demonstrated efficacy and safety in multiple solid advanced cancers. The randomized phase II SCARCE-PRODIGE 60 trial was the first study assessing the use of immunotherapy in combination with chemotherapy in the first-line setting of SCAC.17 Patients with untreated, locally advanced or metastatic SCAC were randomly assigned to either chemotherapy alone (docetaxel, cisplatin and 5-fluorouracil [DCF]) or in combination with atezolizumab. This study did not include patients with HIV infection. There was no improvement in 12-month PFS (44.2% versus 43.2%) or 12-month OS (77.7% versus 80.8%) between chemotherapy in combination with atezolizumab versus chemotherapy alone, respectively. The ORR was also similar between the two groups, 74.6% in the combination arm and 78.1% in the chemotherapy alone arm. There were also higher rates of grade 34 toxicities in the atezolizumab arm (59.0% versus 35.0%). This may be due to the concurrent use of immunotherapy and DCF chemotherapy, which may be mitigated with sequential treatment. This study did not show a benefit for atezolizumab in combination with chemotherapy in the first-line setting of advanced SCAC in a biomarker unselected population. However, it should be noted that there were baseline differences between the two arms, with those in the combination arm having worse prognostic features (i.e. bulkier disease and poorer performance status), which may account for the lack of survival benefit seen with this combination. Further first-line studies assessing the use of chemotherapy in combination with ICI in SCAC are ongoing (see Table 2).12,18,21–26

Ongoing trials

Multiple ICIs have demonstrated efficacy and safety in patients with unresectable locally advanced and metastatic SCAC, mostly in the second- or later-line setting. However, there is growing interest in their use earlier in the treatment paradigm in the first-line setting, in combination with cytotoxic chemotherapy and other agents.

The SCARCE-PRODIGE 60 trial, as outlined above, is the only trial to report on the use of chemotherapy in combination with ICI in the first-line setting of advanced SCAC. Although this phase II study did not meet its primary endpoint, other studies are assessing the efficacy of chemotherapy in combination with ICI in the first-line setting. The POD1UM-303/InterAACT2 study is a phase III randomized, placebo-controlled trial of chemotherapy alone (carboplatin and paclitaxel) or in combination with retifanlimab in the first-line setting of inoperable locally recurrent or metastatic SCAC in a PD-L1 unselected population.18 This study allows crossover from placebo to retifanlimab in those who progress in the chemotherapy alone arm. This study also includes patients with adequately treated HIV infection. Another randomized, phase III trial of chemotherapy alone (carboplatin and paclitaxel) or in combination with nivolumab in the first-line setting of locally recurrent or metastatic SCAC is ongoing in the EA2176 trial ( Identifier: NCT04444921).24

Studies in other tumour types have shown promise when combining immunotherapy and radiotherapy. The SPARTANA trial ( Identifier: NCT04894370) is assessing the use of spartalizumab (a PD-1 inhibitor) in combination with radiotherapy (single Gy dose) and chemotherapy (DCF) in patients with advanced SCAC.26 This phase II study is based on the biological rationale that radiotherapy-induced DNA damage can promote tumour-specific neoantigen presentation and enhance TIL-mediated cytotoxic tumour cell death.

Given the efficacy of single-agent PD-1 inhibition in chemorefractory SCAC as outlined above, the use of PD-1 inhibitor in combination with cytotoxic T-lymphocyte-associated protein 4 inhibitors, such as ipilimumab, is of particular interest to enhance the immune-mediated response. A phase II trial of nivolumab with or without ipilimumab in treatment-refractory metastatic SCAC is assessing this combination as a chemotherapy-free regimen ( Identifier: NCT02314169).25

There is also growing interest in using ICI in early-stage disease given its efficacy in metastatic SCAC. The current treatment paradigm in this setting is concurrent chemoradiotherapy, and the use of ICI may enhance an antitumour immune effect when combined with both chemotherapy and radiotherapy. The INTERACT-ION trial is a phase II study of ezabenlimab (a PD-1 inhibitor) with chemotherapy (modified DCF), followed by concurrent chemoradiotherapy with capecitabine and mitomycin C ( Identifier: NCT04719988).23 Other clinical trials assessing chemoradiotherapy combined with ICI are ongoing ( Identifier: NCT05060471; Identifier: NCT05374252).21,22


ICIs have shown promise as an effective and safe treatment in patients with advanced SCAC, following progression on first-line chemotherapy. The PD-1 inhibitor retifanlimab is associated with an encouraging response rate (13.8%) regardless of PD-L1 expression or HIV infection, with prolonged survival seen with single-agent retifanlimab in a chemorefractory setting. The efficacy of retifanlimab is comparable to other ICIs studied in this setting, including pembrolizumab and nivolumab. Retifanlimab also appears to be safe in patients with HIV infection, without higher rates of toxicity or loss of control of HIV infection, and can be considered the optimal therapy in this population. The toxicity profile of retifanlimab is similar to that seen with other ICIs, with no new safety signals seen in the POD1UM-202 trial.

As seen in the SCARCE-PRODIGE 60 trial, the use of ICI in combination with chemotherapy in the first-line setting of SCAC has been studied previously without improvement in efficacy and with higher rates of toxicity. However, further studies assessing this are currently ongoing. Chemotherapy in combination with ICI has shown promise in the treatment of other solid tumours, including metastatic lung cancer and gastric cancer. Chemotherapy induction of cellular death and presentation of neo-antigens to promote TILs and promoting cellular death provides the rationale for the ongoing phase III POD1UM-303 trial.

An important factor in the treatment of SCAC is identifying patients who will likely respond to ICIs. There is a paucity of data to support that PD-L1 status can be used as a biomarker of response to ICI in SCAC. Further validation of the use of PD-L1 status as a biomarker is the subject of interest in multiple ongoing clinical trials, including in the POD1UM-303 trial, to provide a personalized approach in the use of ICI to treat advanced SCAC.

Article Information:

Sheela Rao has a consulting/advisory role with Bayer and Roche and she has received travel and accommodation expenses from Incyte and Bayer. Justin Mencel has no financial or non-financial relationships or activities to declare in relation to this article.

Compliance With Ethics

This article involves a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors.

Review Process

Double-blind peer review


The named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.


Sheela Rao, Gastrointestinal Unit, Royal Marsden NHS Foundation Trust, Fulham Road, London, SW3 6JJ, UK. E:


No funding was received in the publication of this article.


This article is freely accessible at ©Touch Medical Media 2023.

Data Availability

Data sharing is not applicable to this article as no datasets were generated or analysed during the writing of this article.




  1. Cancer Research UK. Anal cancer statistics. Available at: (accessed date 20 January 2023).
  2. Daling JR, Madeleine MM, Johnson LG, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer. 2004;101:270–80.
  3. Serup-Hansen E, Linnemann D, Skovrider-Ruminski W, et al. Human papillomavirus genotyping and p16 expression as prognostic factors for patients with american joint committee on cancer stages I to III carcinoma of the anal canal. J Clin Oncol. 2014;32:1812–7.
  4. De Vuyst H, Clifford GM, Nascimento MC, et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: A meta-analysis. Int J Cancer. 2009;124:1626–36.
  5. Abramowitz L, Jacquard A-C, Jaroud F, et al. Human papillomavirus genotype distribution in anal cancer in France: The EDiTH V study. Int J Cancer. 2011;129:433–9.
  6. Clifford GM, Georges D, Shiels MS, et al. A meta-analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale. Int J Cancer. 2021;148:38–47.
  7. Northover J, Glynne-Jones R, Sebag-Montefiore D, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer. 2010;102:1123–8.
  8. Rao S, Sclafani F, Eng C, et al. International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: Interaact. J Clin Oncol. 2020;38:2510–18.
  9. Ghittoni R, Accardi R, Hasan U, et al. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes. 2010;40:1–13.
  10. Partlová S, Bouček J, Kloudová K, et al. Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma. Oncoimmunology. 2015;4:e965570.
  11. Masterson L, Lechner M, Loewenbein S, et al. CD8+ T cell response to human papillomavirus 16 E7 is able to predict survival outcome in oropharyngeal cancer. Eur J Cancer. 2016;67:141–51.
  12. Catenacci DVT, Kang Y-K, Yoon HH, et al. Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A. ESMO Open. 2022;7:100563.
  13. Rao S, Anandappa G, Capdevila J, et al. A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202). ESMO Open. 2022;7:100529.
  14. Marabelle A, Cassier PA, Fakih M, et al. Pembrolizumab for previously treated advanced anal squamous cell carcinoma: Results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. Lancet Gastroenterol Hepatol. 2022;7:446–54.
  15. Morris VK, Salem ME, Nimeiri H, et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): A multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18:446–53.
  16. Lonardi S, Prete AA, Morano F, et al. Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: The CARACAS study. J Immunother Cancer. 2021;9:11.
  17. Kim S, Ghiringhelli F, De La Fouchardiere C, et al. Atezolizumab plus modified DCF (docetaxel, cisplatin, and 5-fluorouracil) as first-line treatment for metastatic or locally advanced squamous cell anal carcinoma: A SCARCE-PRODIGE 60 randomized phase II study. J Clin Oncol. 2022;40(Suppl. 16):3508.
  18. Rao S, Jones M, Bowman J, et al. POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin-paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma. Front Oncol. 2022;12:935383.
  19. Ott PA, Piha-Paul SA, Munster P, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol. 2017;28:1036–41.
  20. Lê LH, Chetty R, Moore MJ. Epidermal growth factor receptor expression in anal canal carcinoma. Am J Clin Pathol. 2005;124:20–3.
  21. Chemoradiotherapy combined with or without PD-1 blockade in anal canal squamous carcinoma patients. identifier: NCT05374252. Available at: (accessed date 23 January 2023).
  22. Neoadjuvant PD-1 blockade combined with chemotherapy followed by concurrent immunoradiotherapy for locally advanced anal canal squamous carcinoma patients. identifier: NCT05060471. Available at: (accessed date 23 January 2023).
  23. Anti-PD-1 and mdcf followed by chemoradiotherapy in patients with stage III squamous cell anal carcinoma. (INTERACT-ION). identifier: NCT04719988. Available at: (accessed date 23 January 2023).
  24. EA2176: phase 3 clinical trial of carboplatin and paclitaxel +/- nivolumab in metastatic anal cancer patients. identifier: NCT04444921. Available at: https:/ (accessed date 20 January 2023).
  25. Nivolumab with or without ipilimumab in treating patients with refractory metastatic anal canal cancer. identifier: NCT02314169. Available at: (accessed date 23 January 2023).
  26. Combination of spartalizumab, mdcf and radiotherapy in patients with metastatic squamous cell anal carcinoma (SPARTANA). identifier: NCT04894370. Available at: (accessed date 23 January 2023).
  27. A study of mdcf in combination or not with atezolizumab in advanced squamous cell anal carcinoma (SCARCE). identifier: NCT03519295. Available at: (accessed date 1 March 2023).

Further Resources

Share this Article
Related Content In Immunotherapy
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72